iHuman Inc. Announces Third Quarter 2022 Unaudited Financial Results

    0
    301

    BEIJING, Dec. 8, 2022 /PRNewswire/ — iHuman Inc. (NYSE: IH) (“iHuman” or the “Company”), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the third quarter ended September 30, 2022.

    Third Quarter 2022 Highlights

    • Revenues were RMB251.5 million (US$35.4 million), compared with RMB259.0 million in the same period last year.
    • Gross profit was RMB177.1 million (US$24.9 million), compared with RMB180.2 million in the same period last year.
    • Operating income reached a record-high of RMB38.5 million (US$5.4 million), a remarkable turnaround compared with an operating loss of RMB43.9 million in the same period last year.
    • Adjusted operating income[1] reached a record-high of RMB42.5 million (US$6.0 million), a remarkable turnaround compared with an adjusted operating loss of RMB41.5 million in the same period last year.
    • Net income reached a record-high of RMB39.5 million (US$5.5 million), a remarkable turnaround compared with a net loss of RMB38.2 million in the same period last year.
    • Adjusted net income[1] reached a record-high of RMB43.5 million (US$6.1 million), a remarkable turnaround compared with an adjusted net loss of RMB35.8 million in the same period last year.
    • Average total MAUs[2] reached a record-high of 20.63 million, a year-over-year increase of 16.7%.

    Dr. Peng Dai, Director and Chief Executive Officer of iHuman, commented, “Building on our momentum in the first half of the year, we are pleased to deliver another set of solid results in the third quarter. Our average total MAUs hit an all-time high, increasing by 17% year-over-year to 20.63 million. The strong growth and continued expansion of our user base not only reflects the growing engagement and activeness of our user community, but also further validates the effectiveness of our focused organic user acquisition strategy. In the quarter, we optimized our domestic product portfolio to continue enhancing user experience and achieved some encouraging progress in our international business. Recently, we launched bekids Puzzle and bekids ABC, two more key milestones on our international roadmap. bekids Puzzle is designed to improve thinking skills in fun and meaningful ways, and provides more visual appeal, entertainment, and challenge than traditional puzzles. bekids ABC is an all-in-one app designed to provide essential early-years enlightenment for children, improving their reading, logic, and social skills. Meanwhile, we are stepping up our efforts to develop new products aligned with international market demand, and expect to gradually roll out these new offerings in the near future. Although our expansion efforts are still in an early stage, we are delighted to see that the business is gaining traction and market recognition. For example, bekids Coloring, an app designed to inspire children’s artistic creativity and develop their visual literacy via fun and interactive drawing activities, has already received two prestigious awards from the “Mom’s Choice Awards” (MCA) and “Parent Tested Parent Approved” (PTPA), two of North America’s best-recognized and most influential family product awards organizations. We believe distinguished acknowledgments like these represent a strong testament to the excellence of bekids Coloring, and will help drive product adoption among international families, and boost market awareness of our Bekids brand as a whole. Our expanded user base in the domestic market, ever-strengthening product pipeline, and growing recognition in the international market further give us confidence in our ability to unlock long-term opportunities and business growth. Going forward, we remain committed to our product-driven growth strategies and will continue to invest in key strategic priorities.”

    Ms. Vivien Weiwei Wang, Director and Chief Financial Officer of iHuman, added, “In the third quarter, we continued to make progress in improving profitability at scale while continuing to drive quality growth. We reached a record-high quarterly adjusted net income of RMB43.5 million, and achieved a third consecutive quarter of profitability. The continued improvement in profitability was primarily driven by our sound operating efficiency initiatives. We better aligned our cost structure with our strategic priorities and improved our operational efficiency by further streamlining key business processes and workflows. For example, by leveraging our strong big data and AI capabilities to personalize product recommendations, we effectively directed user traffic of our flagship products to our newer offerings, elevating our cross-sell opportunities and enhancing user acquisition efficiency. Looking ahead, we will work diligently to innovate new products and remain focused on operational excellence to drive healthy and sustainable business growth.”

    Third Quarter 2022 Unaudited Financial Results

    Revenues

    Revenues were RMB251.5 million (US$35.4 million), a slight decrease of 2.9% from RMB259.0 million in the same period last year.

    Average total MAUs for the quarter were 20.63 million, an increase of 16.7% year-over-year from 17.68 million in the same period last year. The number of paying users[3] for the quarter was 1.65 million.

    Cost of Revenues

    Cost of revenues was RMB74.4 million (US$10.5 million), a decrease of 5.5% from RMB78.8 million in the same period last year.

    Gross Profit and Gross Margin

    Gross profit was RMB177.1 million (US$24.9 million), a slight decrease of 1.7% from RMB180.2 million in the same period last year. Gross margin was 70.4%, compared with 69.6% in the same period last year.

    Operating Expenses

    Total operating expenses were RMB138.6 million (US$19.5 million), a decrease of 38.2% from RMB224.1 million in the same period last year.

    Research and development expenses were RMB71.9 million (US$10.1 million), a decrease of 45.2% from RMB131.1 million in the same period last year, primarily due to cost savings in payroll-related expenses and outsourcing expenses.

    Sales and marketing expenses were RMB41.7 million (US$5.9 million), a decrease of 38.0% from RMB67.2 million in the same period last year, primarily due to an economical and optimized advertising strategy.

    General and administrative expenses were RMB25.0 million (US$3.5 million), a decrease of 2.8% from RMB25.8 million in the same period last year.

    Operating Income

    Operating income was RMB38.5 million (US$5.4 million), compared with an operating loss of RMB43.9 million in the same period last year.

    Excluding share-based compensation expenses, adjusted operating income was RMB42.5 million (US$6.0 million), compared with an adjusted operating loss of RMB41.5 million in the same period last year.

    Net Income

    Net income was RMB39.5 million (US$5.5 million), compared with a net loss of RMB38.2 million in the same period last year.

    Adjusted net income was RMB43.5 million (US$6.1 million), compared with an adjusted net loss of RMB35.8 million in the same period last year.

    Basic and diluted net income per ADS were RMB0.74 (US$0.10) and RMB0.73 (US$0.10), respectively, compared with basic and diluted net loss per ADS of RMB0.72 in the same period last year. Each ADS represents five Class A ordinary shares of the Company.

    Adjusted diluted net income per ADS was RMB0.80 (US$0.11), compared with adjusted diluted net loss per ADS of RMB0.67 in the same period last year.

    Deferred Revenue and Customer Advances

    Deferred revenue and customer advances were RMB340.7 million (US$47.9 million) as of September 30, 2022, compared with RMB303.0 million as of December 31, 2021.

    Cash, Cash Equivalents and Time Deposits

    Cash, cash equivalents and time deposits were RMB949.6 million (US$133.5 million) as of September 30, 2022, compared with RMB855.4 million as of December 31, 2021.

    [1] “Adjusted operating income” and “adjusted net income” exclude share-based compensation expenses. Please see “Non-GAAP Financial Measures” and “Unaudited Reconciliation of GAAP and non-GAAP Results” at the end of this press release.

    [2] “Average total MAUs” refers to the monthly average of the sum of the MAUs of each of the Company’s apps during a specific period, which is counted based on the number of unique mobile devices through which such app is accessed at least once in a given month, and duplicate access to different apps is not eliminated from the total MAUs calculation.

    [3] “Paying users” refers to users who paid subscription fees for premium content on any of the Company’s apps during a specific period; a user who makes payments across different apps using the same registered account is counted as one paying user, and a user who makes payments for the same app multiple times in the same period is counted as one paying user.

    Modification of Exercise Prices of Share Options

    In September 2022, to provide additional incentives to the Company’s employees, the Company modified the exercise prices for eligible outstanding options as of September 30, 2022, originally granted with exercise prices above US$0.2 per Class A ordinary share to the employees. Upon the modification, the exercise prices of these options were decreased to US$0.2 per Class A ordinary share, while other terms remained unchanged.

    Extension of Share Repurchase Program

    As announced on December 21, 2021, the Company’s board of directors (the “Board”) has authorized a share repurchase plan under which the Company may repurchase up to US$10 million of its shares over the next 12 months. Given its confidence in the Company’s business prospects, the Board has authorized an extension of the share repurchase program for another 12 months until December 31, 2023. Pursuant to the extended share repurchase program, the Company’s proposed repurchases may be made from time to time through open market transactions at prevailing market prices, in privately negotiated transactions, in block trades and/or through other legally permissible means, depending on the market conditions and in accordance with applicable rules and regulations. The timing and dollar amount of repurchase transactions will be subject to the Securities and Exchange Commission (the “SEC”) Rule 10b-18 and/or Rule 10b5-1 requirements. The Board will continue to review the extended share repurchase program periodically, and may authorize adjustments to its terms and size. The Company expects to continue to fund the repurchases under the extended share repurchase program with its existing cash balance.

    Exchange Rate Information

    The U.S. dollar (US$) amounts disclosed in this press release, except for those transaction amounts that were actually settled in U.S. dollars, are presented solely for the convenience of the reader. The conversion of Renminbi (RMB) into US$ in this press release is based on the exchange rate set forth in the H.10 statistical release of the Board of Governors of the Federal Reserve System as of September 30, 2022, which was RMB7.1135 to US$1.00. The percentages stated in this press release are calculated based on the RMB amounts.

    Non-GAAP Financial Measures

    iHuman considers and uses non-GAAP financial measures, such as adjusted operating income, adjusted net income and adjusted diluted net income per ADS, as supplemental metrics in reviewing and assessing its operating performance and formulating its business plan. The presentation of non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). iHuman defines adjusted operating income, adjusted net income and adjusted diluted net income per ADS as operating income, net income and diluted net income per ADS excluding share-based compensation expenses, respectively. Adjusted operating income, adjusted net income and adjusted diluted net income per ADS enable iHuman’s management to assess its operating results without considering the impact of share-based compensation expenses, which are non-cash charges. iHuman believes that these non-GAAP financial measures provide useful information to investors in understanding and evaluating the Company’s current operating performance and prospects in the same manner as management does, if they so choose.

    Non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. Non-GAAP financial measures have limitations as analytical tools, which possibly do not reflect all items of expense that affect our operations. Share-based compensation expenses have been and may continue to be incurred in our business and are not reflected in the presentation of the non-GAAP financial measures. In addition, the non-GAAP financial measures iHuman uses may differ from the non-GAAP measures used by other companies, including peer companies, and therefore their comparability may be limited. The presentation of these non-GAAP financial measures is not intended to be considered in isolation from or as a substitute for the financial information prepared and presented in accordance with GAAP.

    Safe Harbor Statement

    This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates”  and similar statements. Statements that are not historical facts, including statements about iHuman’s beliefs and expectations, are forward-looking statements. Among other things, the description of the management’s quotations in this announcement contains forward-looking statements. iHuman may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials, and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: iHuman’s growth strategies; its future business development, financial condition and results of operations; its ability to continue to attract and retain users, convert non-paying users into paying users and increase the spending of paying users, the trends in, and size of, the market in which iHuman operates; its expectations regarding demand for, and market acceptance of, its products and services; its expectations regarding its relationships with business partners; general economic and business conditions; regulatory environment; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in iHuman’s filings with the SEC. All information provided in this press release is as of the date of this press release, and iHuman does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

    About iHuman Inc.

    iHuman Inc. is a leading provider of tech-powered, intellectual development products in China that is committed to making the child-rearing experience easier for parents and transforming cognitive development into a fun journey for children. Benefiting from a deep legacy that combines over two decades of experience in the parenthood industry, superior original content, advanced high-tech innovation DNA and research & development capabilities with cutting-edge technologies, iHuman empowers parents with tools to make the child-upbringing experience more efficient. iHuman’s unique, fun and interactive product offerings stimulate children’s natural curiosity and exploration. The Company’s comprehensive suite of innovative and high-quality products include self-directed apps, interactive content and smart devices that cover a broad variety of areas to develop children’s abilities in speaking, critical thinking, independent reading and creativity, and foster their natural interest in traditional Chinese culture. Leveraging advanced technological capabilities, including 3D engines, AI/AR functionality, and big data analysis on children’s behavior & psychology, iHuman believes it will continue to provide superior experience that is efficient and relieving for parents, and effective and fun for children, in China and all over the world, through its integrated suite of tech-powered, intellectual development products.

    For more information about iHuman, please visit https://ir.ihuman.com/.

    For investor and media enquiries, please contact:

    iHuman Inc.
    Mr. Justin Zhang
    Investor Relations Director
    Phone: +86 10 5780-6606
    E-mail: ir@ihuman.com

    Christensen
    In China
    Mr. Eric Yuan
    Phone: +86-13801110739
    E-mail: eric.yuan@christensencomms.com 

    In the US
    Ms. Linda Bergkamp
    Phone: +1-480-614-3004
    E-mail: linda.bergkamp@christensencomms.com

    iHuman Inc.
      

    UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
      

    (Amounts in thousands of Renminbi (“RMB”) and U.S. dollars (“US$”)

    except for number of shares, ADSsper share and per ADS data)

    December 31,

    September 30,

    September 30,

    2021

    2022

    2022

    RMB

    RMB

    US$

    ASSETS

    Current assets

    Cash and cash equivalents 

    855,362

    878,606

    123,512

    Time deposits

    70,998

    9,981

    Accounts receivable, net

    56,132

    76,215

    10,714

    Inventories, net

    28,054

    16,520

    2,322

    Amounts due from related parties

    2,845

    4,193

    589

    Prepayments and other current assets

    72,851

    93,726

    13,176

    Total current assets

    1,015,244

    1,140,258

    160,294

    Non-current assets

    Property and equipment, net

    12,286

    9,801

    1,378

    Intangible assets, net

    27,287

    26,878

    3,778

    Operating lease right-of-use assets

    38,237

    17,311

    2,434

    Long-term investment

    26,333

    3,702

    Amounts due from related parties

    4,223

    Other non-current assets

    3,604

    4,108

    578

    Total non-current assets

    85,637

    84,431

    11,870

    Total assets

    1,100,881

    1,224,689

    172,164

    LIABILITIES

    Current liabilities

    Accounts payable

    30,536

    13,912

    1,956

    Deferred revenue and customer advances

    302,980

    340,737

    47,900

    Amounts due to related parties

    8,853

    8,922

    1,254

    Accrued expenses and other current liabilities

    115,895

    108,037

    15,188

    Current operating lease liabilities

    24,669

    10,490

    1,475

    Total current liabilities

    482,933

    482,098

    67,773

    Non-current liabilities

    Non-current operating lease liabilities

    9,577

    3,197

    449

    Total non-current liabilities

    9,577

    3,197

    449

    Total liabilities

    492,510

    485,295

    68,222

    SHAREHOLDERS’ EQUITY

    Ordinary shares (par value of US$0.0001 per share,
      700,000,000 Class A shares authorized as of December
      31, 2021 and September 30, 2022; 125,122,382 Class A
      shares issued and 123,852,667 outstanding as of
      December 31, 2021; 125,122,382 Class A shares issued
      and 122,150,597 outstanding as of September 30, 2022;
      200,000,000 Class B shares authorized, 144,000,000
      Class B ordinary shares issued and outstanding as of
      December 31, 2021 and September 30, 2022; 100,000,000
      shares (undesignated) authorized, nil shares
      (undesignated) issued and outstanding as of December 31,

      2021 and September 30, 2022)

    185

    185

    26

    Additional paid-in capital

    1,066,052

    1,074,051

    150,988

    Treasury stock

    (164)

    (5,711)

    (803)

    Accumulated other comprehensive income (loss)

    (34,677)

    19,508

    2,742

    Accumulated deficit

    (423,025)

    (348,639)

    (49,011)

    Total shareholders’ equity

    608,371

    739,394

    103,942

    Total liabilities and shareholders’ equity

    1,100,881

    1,224,689

    172,164

    iHuman Inc.

       

    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
      

    (Amounts in thousands of Renminbi (“RMB”) and U.S. dollars (“US$”)

    except for number of shares, ADSs, per share and per ADS data)

    For the three months ended

    For the nine months ended

    September 30,

    June 30,

    September 30,

    September 30,

    September 30,

    September 30,

    September 30,

    2021

    2022

    2022

    2022

    2021

    2022

    2022

    RMB

    RMB

    RMB

    US$

    RMB

    RMB

    US$

    Revenues

    258,983

    230,607

    251,527

    35,359

    706,900

    724,813

    101,893

    Cost of revenues

    (78,785)

    (67,417)

    (74,422)

    (10,462)

    (211,185)

    (214,636)

    (30,173)

    Gross profit

    180,198

    163,190

    177,105

    24,897

    495,715

    510,177

    71,720

    Operating expenses

    Research and development expenses

    (131,088)

    (78,201)

    (71,859)

    (10,102)

    (306,253)

    (246,685)

    (34,678)

    Sales and marketing expenses

    (67,216)

    (33,530)

    (41,669)

    (5,858)

    (165,441)

    (111,105)

    (15,619)

    General and administrative expenses

    (25,761)

    (28,849)

    (25,035)

    (3,519)

    (67,694)

    (79,942)

    (11,238)

    Total operating expenses

    (224,065)

    (140,580)

    (138,563)

    (19,479)

    (539,388)

    (437,732)

    (61,535)

    Operating income (loss)

    (43,867)

    22,610

    38,542

    5,418

    (43,673)

    72,445

    10,185

    Other income, net

    5,695

    2,917

    9,611

    1,351

    14,361

    15,875

    2,232

    Income (loss) before income taxes

    (38,172)

    25,527

    48,153

    6,769

    (29,312)

    88,320

    12,417

    Income tax benefit (expenses)

    (23)

    (3,737)

    (8,675)

    (1,220)

    170

    (13,934)

    (1,959)

    Net income (loss)

    (38,195)

    21,790

    39,478

    5,549

    (29,142)

    74,386

    10,458

    Net income (loss) per ADS:

       – Basic

    (0.72)

    0.41

    0.74

    0.10

    (0.55)

    1.39

    0.20

       – Diluted

    (0.72)

    0.40

    0.73

    0.10

    (0.55)

    1.38

    0.19

    Weighted average number of ADSs:

       – Basic

    53,324,476

    53,308,924

    53,240,710

    53,240,710

    53,324,476

    53,341,120

    53,341,120

       – Diluted

    53,324,476

    53,958,284

    54,114,651

    54,114,651

    53,324,476

    54,043,728

    54,043,728

    Total share-based compensation expenses included in:

    Cost of revenues

    244

    39

    77

    11

    768

    180

    25

    Research and development expenses

    (24)

    801

    2,045

    287

    5,211

    3,813

    536

    Sales and marketing expenses

    767

    430

    698

    98

    2,930

    1,040

    146

    General and administrative expenses

    1,379

    762

    1,187

    167

    4,740

    2,963

    417

    iHuman Inc.
      

    UNAUDITED RECONCILIATION OF GAAP AND NON-GAAP RESULTS
      

    (Amounts in thousands of Renminbi (“RMB”) and U.S. dollars (“US$”)

    except for number of shares, ADSs, per share and per ADS data)

    For the three months ended

    For the nine months ended

    September 30,

    June 30,

    September 30,

    September 30,

    September 30,

    September 30,

    September 30,

    2021

    2022

    2022

    2022

    2021

    2022

    2022

    RMB

    RMB

    RMB

    US$

    RMB

    RMB

    US$

    Operating income (loss)

    (43,867)

    22,610

    38,542

    5,418

    (43,673)

    72,445

    10,185

    Share-based compensation expenses

    2,366

    2,032

    4,007

    563

    13,649

    7,996

    1,124

    Adjusted operating income (loss)

    (41,501)

    24,642

    42,549

    5,981

    (30,024)

    80,441

    11,309

    Net income (loss)

    (38,195)

    21,790

    39,478

    5,549

    (29,142)

    74,386

    10,458

    Share-based compensation expenses

    2,366

    2,032

    4,007

    563

    13,649

    7,996

    1,124

    Adjusted net income (loss)

    (35,829)

    23,822

    43,485

    6,112

    (15,493)

    82,382

    11,582

    Diluted net income (loss) per ADS

    (0.72)

    0.40

    0.73

    0.10

    (0.55)

    1.38

    0.19

    Impact of non-GAAP adjustments

    0.05

    0.04

    0.07

    0.01

    0.26

    0.14

    0.02

    Adjusted diluted net income (loss) per ADS

    (0.67)

    0.44

    0.80

    0.11

    (0.29)

    1.52

    0.21

    Weighted average number of ADSs – diluted

    53,324,476

    53,958,284

    54,114,651

    54,114,651

    53,324,476

    54,043,728

    54,043,728

    Weighted average number of ADSs – adjusted

    53,324,476

    53,958,284

    54,114,651

    54,114,651

    53,324,476

    54,043,728

    54,043,728

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ihuman-inc-announces-third-quarter-2022-unaudited-financial-results-301697881.html

    Source: iHuman Inc.